Professional Seasonal Analysis for Trading

Karyopharm Therapeutics Inc. - Common Stock (KPTI)

Seasonality Analysis

Stocks 13 Years Analyzed

Karyopharm Therapeutics Inc. - Common Stock Annual Seasonality Statistics

-1.23%
Avg Annual Return
42.6%
Avg Monthly Win Rate
5/12
Positive Months
13
Years Analyzed

Karyopharm Therapeutics Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January -4.89%
38%
Very Weak
February 3.29%
46%
Weak
March -3.65%
46%
Weak
April 2.07%
38%
Weak
May WORST -6.40%
25%
Very Weak
June 2.11%
58%
Moderate
July -2.58%
33%
Very Weak
August 5.54%
50%
Weak
September -1.97%
33%
Very Weak
October -2.57%
42%
Weak
November BEST 10.32%
62%
Strong
December -2.51%
38%
Very Weak

Karyopharm Therapeutics Inc. - Common Stock 2026 vs Historical Pattern

Current Position
70.7
Historical Avg Position
43.16
Deviation
+27.54
Performance
Significantly Above Average

Karyopharm Therapeutics Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for KPTI with overlay patterns, custom date ranges, and more.

Create Free Account

Karyopharm Therapeutics Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Karyopharm Therapeutics Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for KPTI across multiple timeframes.

Create Free Account

About Karyopharm Therapeutics Inc. - Common Stock (KPTI) Seasonality

Karyopharm Therapeutics Inc. - Common Stock (KPTI) has been analyzed using 13 years of historical data to identify seasonal patterns. Classified under Stocks, Karyopharm Therapeutics Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Karyopharm Therapeutics Inc. - Common Stock is historically November, with an average return of 10.32% and a win rate of 62%. Conversely, May tends to be the weakest month, averaging -6.40% return.

Looking at the full calendar year, Karyopharm Therapeutics Inc. - Common Stock has an average annual return of -1.23% with an overall monthly win rate of 42.6%. Out of 12 months, 5 typically show positive average returns.

The seasonal pattern for Karyopharm Therapeutics Inc. - Common Stock has a consistency score of 50.1 (Fair), based on 14 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Karyopharm Therapeutics Inc. - Common Stock Seasonality FAQ

What is the best month to buy Karyopharm Therapeutics Inc. - Common Stock (KPTI)?

Historically, November has been the best month for Karyopharm Therapeutics Inc. - Common Stock, with an average return of 10.32% and a win rate of 62%. However, past performance does not guarantee future results.

What is the worst month for Karyopharm Therapeutics Inc. - Common Stock (KPTI)?

Based on historical data, May has been the weakest month for Karyopharm Therapeutics Inc. - Common Stock, with an average return of -6.40%. This is a historical observation and does not guarantee future results.

How reliable is KPTI seasonality data?

The seasonality analysis for Karyopharm Therapeutics Inc. - Common Stock is based on 13 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Karyopharm Therapeutics Inc. - Common Stock seasonality in my trading?

Use Karyopharm Therapeutics Inc. - Common Stock (KPTI) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.